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Proteus mirabilis urease catalyzes the hydrolysis of urea to CO2 and NH3, resulting in urinary stone forma-
tion in individuals with complicated urinary tract infections. UreR, a member of the AraC family, activates
transcription of the genes encoding urease enzyme subunits and accessory proteins, ureDABCEFG, as well as
its own transcription in the presence of urea. Based on sequence homology with AraC, we hypothesized that
UreR contains both a dimerization domain and a DNA-binding domain. A translational fusion of the leucine
zipper dimerization domain (amino acids 302 to 350) of C/EBP and the C-terminal half of UreR (amino acids
164 to 293) activated transcription from the ureD promoter (pureD) and bound to a 60-bp fragment containing
pureD, as analyzed by gel shift. These results were consistent with the DNA-binding specificity residing in the
C-terminal half of UreR and dimerization being required for activity. To localize the dimerization domain of
UreR, a translational fusion of the DNA-binding domain of the LexA repressor (amino acids 1 to 87) and the
N-terminal half of UreR (amino acids 1 to 182) was constructed and found to repress transcription from
psulA-lacZ (sulA is repressed by LexA) and bind to the sulA operator site, as analyzed by gel shift. Since LexA
binds this site only as a dimer, the UreR1–182-LexA1–87 fusion also must dimerize to bind psulA. Indeed, purified
UreR-Myc-His eluted from a gel filtration column as a dimer. Therefore, we conclude that the dimerization
domain of UreR is located within the N-terminal half of UreR. UreR contains three leucines that mimic the
leucines that contribute to dimerization of AraC. Mutagenesis of Leu147, Leu148, or L158 alone did not sig-
nificantly affect UreR function. In contrast, mutagenesis of both Leu147 and Leu148 or all three Leu residues
resulted in a 85 or 94% decrease, respectively, in UreR function in the presence of urea (P < 0.001). On the
contrary, His102 and His175 mutations of UreR resulted in constitutive induction in the absence of urea. We
conclude that a dimerization domain resides in the N-terminal half of the polypeptide, that Leu residues may
contribute to this function, and that sequences within the C-terminal half of UreR are responsible for DNA
binding to the urease promoter regions. Selected His residues also contribute significantly to UreR function.
Proteus mirabilis infects the urinary tract of humans and is
most commonly responsible for causing disease in individuals
with structural abnormalities of the urinary tract or in patients
who undergo long-term catheterization (16). Cystitis, acute
pyelonephritis, and urinary stone formation are all possible
consequences of P. mirabilis infection (17).
P. mirabilis produces a urea-inducible urease, a high-molec-
ular-weight, multimeric, cytoplasmic nickel metalloenzyme.
Urease catalyzes the hydrolysis of urea to ammonia and carbon
dioxide (18). During the course of infection, the production of
ammonia by urea hydrolysis raises the pH in the local environ-
ment, subsequently precipitating polyvalent ions that are nor-
mally soluble in urine. The result is the formation of urinary
stones. The elevated pH also creates an environment that is
more favorable for growth of this species (4). Increased am-
monia production can also lead to acute inflammation with
possible tissue necrosis (18).
The P. mirabilis urease gene cluster is found in single copy
on the chromosome and consists of eight contiguous genes,
ureRDABCEFG (12, 19, 24). The ureA (UreA, 11 kDa), ureB
(UreB, 12 kDa), and ureC (UreC, 61 kDa) genes encode the
structural polypeptides required for the assembly of a catalyt-
ically inactive urease apoenzyme (18). The accessory genes,
ureD (UreD, 31 kDa), ureE (UreE, 18 kDa), ureF (UreF, 23
kDa), and ureG (UreG, 22 kDa), encode proteins required for
insertion of nickel ions into the metalloenzyme resulting in
catalytically active urease (18). The urease gene cluster is reg-
ulated by the gene product of ureR (UreR, 33 kDa).
P. mirabilis UreR and the plasmid-encoded UreR found in
Escherichia coli are positive transcriptional activators of the
urease genes. The two proteins share 70% amino acid identity
(6) and are functionally interchangeable in the activation of
transcription from the ureR (pureR) and ureD (pureD) promoters
in both the P. mirabilis and plasmid-encoded urease gene clus-
ters (6). The UreR binding sites of both promoters have the
consensus sequence T(A/G)(T/C)(A/T)(T/G)(C/T)T(A/T)(T/A)
ATTG (25). Both UreR proteins have been shown to activate
transcription from pureD in the presence of urea (11, 6). In ad-
dition, UreR regulates its own transcription in the presence of
urea from pureR in the direction opposite the rest of the gene
cluster (6). In the absence of urea induction, H-NS represses
ureR expression (3). Because UreR activates transcription in a
urea-inducible manner, it is hypothesized that UreR binds
urea; however, this has not been directly demonstrated.
UreR is a member of the AraC family of transcriptional
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regulators and contains a putative helix-turn-helix in addition
to an AraC signature sequence (5, 19). The AraC signature
sequence, found within all AraC family members, is a second
helix-turn-helix that is hypothesized to also bind DNA (7).
Moreover, UreR also contains three conserved leucine resi-
dues (Leu147, Leu148, and Leu158) in the same relative loca-
tion with the same spatial distance relative to each other as in
AraC (Leu150, Leu151, and Leu161). These leucine residues
are critical for AraC dimerization (23), and we therefore also
hypothesize that UreR dimerizes via this mechanism. In the
presence of arabinose, AraC uses these three critical leucines
for dimerization via an antiparallel coiled-coil in a “knobs-into-
holes” manner, as elucidated by X-ray crystallographic studies
(23). This coiled-coil is also the primary dimerization face in
the absence of arabinose, shown by both size exclusion chro-
matography and sedimentation velocity analytical ultracentrif-
ugation of an AraC mutant with mutations in Leu150, Leu151,
Asn154, and Leu161 (15). A secondary dimerization face in the
b barrel of AraC is evident; however, it does not appear to
represent the primary means of dimer interaction (15).
AraC contains two separate and independent domains, each
with a distinct function, namely, dimerization and DNA bind-
ing; UreR is predicted to have similar domains with similar
functions. Previously, chimeric proteins containing the two do-
mains of AraC to characterize each of the domain’s functions
were synthesized (2). The predicted AraC DNA-binding do-
main was fused to C/EBP, a known eukaryotic transcriptional
activator that dimerizes via a leucine zipper. The C/EBP-AraC
fusion was found to bind to pBAD and activate transcription (2).
The hypothesized AraC dimerization domain was fused to the
LexA DNA-binding domain. This fusion was predicted to
mimic full-length LexA and demonstrated the need for dimer-
ization in order to repress transcription of genes normally
turned off by LexA. A chromosomal transcriptional fusion of
psulA to lacZ was repressed in the presence of the AraC-LexA
fusion protein. This strategy was used to identify both domains
of AraC (2).
In this study, we constructed fusion proteins to identify pu-
tative domains of UreR and assign dimerization and DNA-
binding functions to each of the domains as well as identifying
key amino acid residues involved in dimerization and urea
induction.
MATERIALS AND METHODS
Chemicals and enzymes. All enzymes were purchased from Life Technologies
(Rockville, Md.) or New England Biolabs (Beverly, Mass.). All chemicals were
purchased from Sigma-Aldrich (St. Louis, Mo.) unless otherwise noted. The DIG
(digoxigenin) gel shift kit was obtained from Amersham Pharmacia Biotech
(Piscataway, N.J.).
Bacterial strains and growth conditions. Bacterial strains used in this study are
listed in Table 1. Bacteria were grown either in Luria-Bertani (LB) broth at 37°C
with aeration in a shaking incubator (200 rpm) or on LB plates containing 1.5%
agar at 37°C. Plates and media were supplemented with the antibiotic chloram-
phenicol (10 mg/ml), tetracycline (7.5 mg/ml), ampicillin (100 mg/ml), or kana-
mycin (50 mg/ml).
PCR amplification of DNA used to make fusion proteins. PCR primers are
listed in Table 2. The amplification protocol for PCRs was as follows: denatur-
ation, 94°C, 3 min; annealing, 50 to 55°C, 45 s; elongation, 72°C, 1 min; for 30
cycles.
Cloning of PCR products. PCR products were ligated into pCR-BluntII-
TOPO (Invitrogen, Carlsbad, Calif.). Inserts were excised using the appropriate
restriction enzymes (either NcoI-BamHI, BamHI-XhoI, NcoI-XhoI, or NcoI-
HindIII) and separated by agarose gel electrophoresis. PCR amplification prod-
ucts for the inserts encoding C/EBP302–350-Myc-His and LexA1–87-Myc-His were
digested with restriction enzymes; Table 2 lists inserts and restriction enzymes
used. All constructs use an NcoI site to ligate into the vector at the gene sequence
encoding the start codon. A BamHI site is at the junction of the gene sequences
encoding the domains in both C/EBP302–350-UreR164–293 and UreR1–182-
LexA1–87. All constructs except the gene sequences encoding UreR-Myc-His,
UreR164–293-Myc-His, C/EBP302–350-Myc-His, LexA1–87-Myc-His, L147A-L148-
Myc-His, and L147A-L148A-L158A-Myc-His, which use a 39 HindIII site, con-
tain a XhoI site at the 39 end for cloning into the expression vector. Inserts were
purified using a Qiaquick gel extraction kit (Qiagen) and ligated into either
pBAD/MHA or pSE380 (Invitrogen). Plasmids were introduced into the corre-
sponding laboratory strain by CaCl2 transformation (21). The LexA1–87-Myc-His
gene sequence was ligated into pBAD/MHA to take advantage of the Myc-His
epitopes. After transformation, the pBAD vector containing the gene sequence
encoding LexA1–87-Myc-His was purified using a Qiagen miniprep kit. The plas-
mid was then used in a PCR with primers to amplify the gene sequence for
LexA1–87-Myc-His. The PCR product was then cut with NcoI and XhoI and
ligated into the NcoI and XhoI sites in pSE380.
Construction of pureD-lacZ reporter plasmid. A low-copy-number ureD-lacZ
fusion reporter plasmid compatible with pBAD-Myc-His was constructed. Prim-
ers MOB906 and MOB915 were used to PCR amplify an approximately 4.3 kb
DNA fragment from plasmid pDR10 ureD-lacZ (11) under the following condi-
tions: 95°C denaturation, 54°C annealing, and 72°C elongation for 30 cycles,
using Vent DNA polymerase in the presence of 1 mM MgSO4. The PCR product
was gel purified and ligated to PCR-Blunt (Invitrogen), forming pCC026.
pCC026 was digested with EcoRI, and the 4.3-kb DNA fragment encoding
ureD-lacZ was ligated to an EcoRI-digested derivative of pACYC184 that had
previously been cut with PvuII and religated (thus, it does not encode a func-
tional chloramphenicol acetyltransferase). The resulting recombinant plasmid,
pCC042, carries a tetracycline resistance marker and encodes a ureD-lacZ tran-
scriptional fusion that is activated in the presence of UreR and urea.
TABLE 1. E. coli strains and plasmids used in this study
Strain/plasmid Description Referenceor source
E. coli strains
DH5a F2 f80dlacZDM15 D(lacZYA-argF)
U169 deoR recA 1 endA 1 hsdR17
(rk
2 mk
1) phoA supE44 l 2thi-1
gyrA96 relA1
Top10 F2 mcrAD(mrr-hsdRMS-mcrBC)
f80lacZDM15 DlacX74 deoR recA1
araD139 D(ara-leu)7697 galU galK
rpsL(Strr) endA1 nupG
JL1436 F9 laclq lacZDM15::Tn9/lexA71::Tn5
recA1 sulA211 (lsulA::lacZ cl ind2)
2
Plasmids
pSE380 Invitrogen
pBAD/Myc-His A Invitrogen
pCC042 pureD-lacZ reporter construct This work
pSE380-lexA 2
pSE380-lexA-C/EBP 2
pCP015 C/EBP302–350-UreR164–293-pBAD This work
pCP016 Full UreR-pBAD This work
pCP018 Full UreR-pSE380 This work
pCP019 UreR1–182-LexA1–87-pSE380 This work
pCP025 LexA1–87-pSE380 This work
pCP026 C/EBP302–350-pBAD This work
pCP029 L147A-L148A UreR This work
pCP030 L147A UreR This work
pCP031 L148A UreR This work
pCP051 UreR164–293-pBAD This work
pCP056 UreRHis175Ala This work
pCP059 UreR-Myc-His-pBAD This work
pCP063 UreRHis102Ala This work
pCP071 UreR164–293-Myc-His-pBAD This work
pCP072 C/EBP302–350-Myc-His-pBAD This work
pCP073 LexA1–87-Myc-His-pSE380 This work
pCP079 L147A-L148A UreR-Myc-His This work
pCP086 L158A UreR This work
pCP088 L147A-L148A-L158A UreR This work
pCP089 L147A-L148A-L158A UreR-Myc-His This work
VOL. 183, 2001 IDENTIFICATION OF THE DOMAINS OF UreR 4527
TABLE 2. PCR primers used in this study
Primer
no. Primer sequence Gene
Enzyme
cleaved Construct
906 59 CGAAATACGGGCAGACATGG39 pureD-lacZ reporter (ureR-ureD intergenic)
915 59 AGGCAAGTTCAAAATGAACATGG39 pureD-lacZ reporter (ureR-ureD intergenic)
1126 59 CCATGGAATACAAACACATACTTTCTTCTAAC 39 ureR 59 NcoI UreR
UreR-Myc-His
UreR1–182-LexA1–87
L147A-L148A
L147A
L148A
L147A-L148A-Myc-His
UreRHis175Ala
UreRHis102Ala
L158A
L147A-L148A-L158A
L147A-L148A-L158A-Myc-His
1128 59 GGATCCATGAAAGCGTTAACGGCCAGGCAACAA39 lexA 59 BamHI UreR1–182-LexA1–87
1129 59 CTCGAGCTATGGTTCACCGGCAGCCACACGACCTAC 39 lexA 39 Xhol UreR1–182-LexA1–87
LexA1–87
1132 59 CCATGGAGAAAGCCAAACAGCGCAACGTGGAGACG 39 C/EBP 59 Ncol C/EBP302–350-UreR164–293
C/EBP302–350
C/EBP302–350-Myc-His
1133 59 GGATCCCAAGGAGCTCTCAGGCAGCTGGCGGAA 39 C/EBP 39 BamHI C/EBP302–350-UreR164–293
C/EBP302–350
1594 59 GGATCCTTGCGGATCTTGTGTTATTAGATGAGT 39 ureR 39 BamHI UreR1–182-LexA1–87
1595 59 GGATCCAATTATGATGAGCCAAAAAATCAGGCG 39 ureR 59 BamHI C/EBP302–350-UreR164–293
1596 59 CTCGAGTTAAAATACTTTTTTTATTGATTCGTC 39 ureR 39 Xhol C/EBP302–350-UreR164–293
UreR
L147A and L148A
L147A
L148A
L158A
L147A-L148A-L158A
UreRHis175Ala
UreRHis102Ala
UreR164–293
1634 59 AGCCTCTTTTTTATTGCGGCGGCGGTTTATCACGAA 39 ureR L147A-L148A
L147A-L148A-Myc-His
L147A-L148A-L158A
L147A-L148A-L158A-Myc-His
1635 59 TTCGTGATAAACCGCCGCCGCAATAAAAAAGAGGCT 39 ureR L147A-L148A
L147A-L148A-Myc-His
L147A-L148A-L158A
L147A-L148A-L158A-Myc-His
1636 59 AGCCTCTTTTTTATTGCGCTGGCGGTTTATCAC 39 ureR L147A
1637 59 GTGATAAACCGCCAGCGCAATAAAAAAGAGGCT 39 ureR L147A
1638 59 CTCTTTTTTATTTTGGCGGCGGTTTATCACGAA 39 ureR L148A
1639 59 TTCGTGATAAACCGCCGCCAAAATAAAAAAGAG 39 ureR L148A
1646 59 CCATGGCAAAAGCGTTAACGGCCAGGCAACAA 39 lexA 59 NcoI LexA1–87
1647 59 CTCGAGCAAGGAGCTCTCAGGCAGCTGGCGGAA 39 C/EBP 39 Xhol C/EBP302–350
1663 59 AATCAGGCGATCACTGCTCTAATAACACAAGAT 39 ureR UreRHis175Ala
1664 59 ATCTTGTGTTATTAGAGCAGTGATCGCCTGATT 39 ureR UreRHis175Ala
1712 59 CCATGGCAAATTATGATGAGCCAAAAAATCAGGCG 39 ureR 59 NcoI UreR164–293
UreR164–293-Myc-His
1729 59AAGCTTAAATACTTTTTTTATTGATTCGTC 39 ureR 39 HindIII UreR-Myc-His
L147A-L148A-Myc-His
L147A-L148A-L158A-Myc-His
1739 59 ATTTTACACCGAGTTTCAAAAAATGCGTTTTAAATAAACAGCAAT 39 pureD oligo
1740 59 ATTTTTTCTAAACAAATTGCTGTTTATTTAAAACGCATTTTTTGA39 pureD oligo
1749 59 AATCAATCCAGCCCCTGTGAGTTACTGTATGGATGTACAGTACATCCAGTG 39 psulA oligo
1750 59 TGATCTTTGTTGTCACTGGATGTACTGTACATCCATACAGTAACTCACAGG 39 psulA oligo
1797 59 GCGCCGATTACTCGTGCTCTTCCAGATTATCAT 39 ureR UreRHis102Ala
1798 59 ATGATAATCTGGAAGAGCACGAGTAATCGGCGC 39 ureR UreRHis102Ala
1833 59 TTTTTTAAGCTTAAATACTTTTTTTATTGATTCGTC 39 ureR 39 HindIII UreR164–293-Myc-His
1834 59 TTTTTTAAGCTTTGGTTCACCGGCAGCCACACGACCTAC 39 lexA 39 HindIII LexA1–87-Myc-His
1848 59 AAAAAACCATGGAGAAAGCCAAACA 39 C/EBP 59 NcoI C/EBP302–350-Myc-His
1851 59 AAAAAACCATGGCAAAAGCGTTAACGGCCAGGCAACAA 39 lexA 59 NcoI LexA1–87-Myc-His
1852 59 TTTTTTCTCGAGATGATGATGATGATGATGGTC 39 lexA 39 XhoI LexA1–87-Myc-His
1855 59 AAAAAAAAGCTTCAAGGAGCTCTCAGGCAGCTGGCGGAA 39 C/EBP 39 HindIII C/EBP302–350-Myc-His
1883 59 GGGGTCGATATTGCTAATATTTTTCGT 39 ureR L158A
L147A-L148A-L158A
L147A-L148A-L158A-Myc-His
1884 59 ACGAAAAATATTAGCAATATCGACCCC 39 ureR L158A
L147A-L148A-L158A
L147A-L148A-L158A-Myc-His
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Sequencing. Both strands of plasmid constructs were sequenced across each
junction and throughout the insert. Sequencing was done by the Biopolymer
Laboratory at the University of Maryland, Baltimore.
b-Galactosidase expression assays. Fresh medium was inoculated with a sin-
gle colony from LB-agar plates containing the appropriate antibiotics and cul-
tured at 37°C overnight. Overnight cultures were used to inoculate fresh me-
dium. Cultures were monitored until they reached an optical density at 600 nm
(OD600) of ;0.4 to 0.6, at which time inducer (isopropyl-b-D-thiogalactopyrano-
side [IPTG], arabinose, or urea) was added, and cultures were incubated for an
additional hour. Cultures were placed on ice, and the OD600 was measured.
Chloroform (100 ml) and 0.1% sodium dodecyl sulfate (SDS; 50 ml) were added,
and cultures were vortexed. The suspension of permeabilized cells (10 ml) was
added to 990 ml of Z buffer and 200 ml of o-nitrophenyl-b-D-galactopyranoside
(4 mg/ml in H2O). Timed reactions were stopped with 500 ml of 1 M Na2CO3.
OD420 and OD550 measurements were recorded, and Miller units were calcu-
lated (20). All constructs were assayed in three or more independent experi-
ments.
Western blot analysis. Overnight cultures were used to inoculate 4 ml of fresh
LB medium containing the appropriate antibiotics and allowed to grow to mid-
exponential phase. Cultures were induced with the appropriate inducer and
incubated for the indicated time. Cultures were placed on ice. OD600 was de-
termined, and all cultures were adjusted to the same reading. Bacteria were
harvested from 1 ml of culture by centrifugation and resuspended in equivalent
amounts of Laemmli sample buffer. Samples were boiled for 5 min and placed on
ice. The sample volume listed for each experiment was loaded onto a 3.75%
stacking and either a 12.5 or 15% SDS-polyacrylamide gel by the method of
Laemmli (13). SDS running buffer was used for electrophoresis. Gels were
transferred onto Immobilon P membranes in a transfer chamber containing
transfer buffer. Transfer occurred overnight at ;12 V at 4°C. Membranes were
blocked in 5% dry milk in 0.1% TTBS (20 mM Tris-HCl [pH 7.5], 150 mM NaCl,
0.1% Tween 20) for 1 h. Primary antibodies were added to 0.1% TTBS (anti-
LexA, anti-Myc and anti-His, diluted 1:5,000), and membranes were exposed to
antibodies for 2 h at room temperature. Membranes were washed in 0.1% TTBS
three times for 15 min each. Secondary antibodies (anti-mouse immunoglobulin
G coupled to alkaline phosphatase detected anti-Myc and anti-His antibodies;
anti-rabbit immunoglobulin G coupled to alkaline phosphatase detected anti-
LexA antibodies) were placed in 0.1% TTBS (dilution 1:2,000), and membranes
were incubated in the secondary antibodies for 1 h. Membranes were washed
three times for 15 min each in 0.1% TTBS and developed with nitroblue tetra-
zolium–5-bromo-4-chloro-3-indolylphosphate dissolved in H2O (according to the
Western blot protocol as described in reference 1).
Gel shift analysis. Gel shift experiments used either a 60-bp (DNA-binding
domain study) or a 64-bp (dimerization study) double-stranded oligonucleotide
that was synthesized from smaller overlapping oligonucleotide fragments that
were allowed to anneal and extend using Vent polymerase. One microliter of
each reaction was run on a gel for quantification purposes. Both double-stranded
oligonucleotides (3.85 pmol of each) were labeled by the DIG gel shift (Amer-
sham Pharmacia) protocol. Each double-stranded oligonucleotide was diluted to
30 fmol for the binding study.
Overnight cultures were used to inoculate fresh LB medium containing ap-
propriate antibiotics. These cultures were grown to mid-exponential phase. The
appropriate inducer molecule was added and incubated further. The cultures
were placed on ice, and OD600 measurements were taken. OD600 for all cultures
was adjusted to the same reading by using LB medium. Equivalent volumes of
each culture were centrifuged, and the pellet was resuspended in 1 ml of TEN
buffer (10 mM Tris, 1 mM EDTA, 0.1 M NaCl [pH 8.0]). Bacterial suspensions
were disrupted by passage through a French press (18,000 lb/in2). Lysates were
centrifuged (12,000 3 g, 10 min, 4°C). Supernatants were collected and used as
the extract for the binding assay. The binding assay was done as instructed by the
DIG gel shift kit manufacturer (Amersham Pharmacia), using binding buffer,
1 mg of poly(dI-dC), 1 mg of poly-L-lysine, specific extract volume, and 2 ml of the
labeled DNA. Binding reactions for pBAD, UreR, C/EBP302–350-UreR164–293,
and UreR-Myc-His also included 100 mM urea (final concentration). The bind-
ing reactions were run on a preelectrophoresed 6% native polyacrylamide gel in
TAE buffer (0.04 M Tris acetate, 0.001 M EDTA) at 90 V for 1.5 h. The gel was
placed on a Hybond N1 membrane and transferred for 30 min at 400 mA in 13
TAE buffer. The membrane was developed according to the instructions of the
DIG gel shift kit manufacturer (Amersham Pharmacia).
Purification of UreR derivatives. E. coli Top10 transformed with pCP016 or
pCP088 was grown in Luria broth at 37°C. Expression of UreR-Myc-His6 was
induced with 0.2% arabinose when an OD600 of ;0.6 was reached. Following 3 h
of induction, cells were collected by centrifugation and lysed by two passages
through a French pressure cell (18,000 lb/in2). Single-step purification of UreR-
Myc-His6 was performed by nickel-chelating nitrilotriacetic acid affinity chroma-
tography. A single polypeptide of approximately 33 kDa was eluted from the
column with 250 mM imidazole as seen on a Coomassie blue-stained 12% SDS-
polyacrylamide gel (data not shown). In a similar experiment, purified protein
was electrophoresed, transferred to a nitrocellulose membrane, and reacted with
rabbit antiserum specific for the Myc epitope. Western blot anlysis showed that
arabinose-induced E. coli Top10 transformed with either pCP016 or pCP088
produced a single species of 33 kDa, consistent with the predicted size for UreR-
Myc-His6 (see Fig. 3). The band was absent from the vector control under iden-
tical conditions.
Gel filtration chromatography. Gel filtration chromatography was performed
at room temperature on a Sephadex G-75 column (1 by 35 cm) equilibrated with
running buffer (50 mM phosphate [pH 7.5], 150 mM NaCl) at a flow rate of 0.5
ml/min. Molecular weight standards bovine serum albumin (68 kDa) and car-
bonic anhydrase (34.5 kDa) were used to calibrate the column. Purified wild-type
and mutant UreR-Myc-His6 proteins (100 ml of 0.1 mg/ml) were injected onto
the column, and 0.5-ml fractions were collected. The protein elution profile was
monitored by absorbance at 280 nm. An aliquot (100 ml) of each fraction was
transferred to an Immobilon P membrane, and immunoblot analysis performed
with anti-Myc antibodies.
RESULTS
Localization of the UreR DNA-binding domain. To localize
the UreR DNA-binding domain, a protein chimera was con-
structed by fusing the gene sequence encoding the C-terminal
half of UreR to the gene sequence encoding the leucine zipper
dimerization domain of C/EBP (Fig. 1; primers are listed in
Table 2). All translational fusion constructs were cloned into
the E. coli arabinose-inducible expression vector pBAD/Myc-
His A (Invitrogen) (Table 1). A pureD-lacZ plasmid reporter
was constructed in pACYC184 to assay specific induction of
the urease gene cluster, using b-galactosidase activity as the
readout. Both reporter plasmid and pBAD constructs with and
without insert were transformed into E. coli Top10.
The C/EBP302–350-UreR164–293 fusion chimera was tested
for its ability to bind to pureD and activate transcription. The
C/EBP302–350-UreR164–293 fusion activated transcription from
FIG. 1. Schematic of fusion constructs. The domain structure of
each of the chimeric proteins is shown; the amino acid residue number
is labeled at each boundary. A BamHI restriction site (coding for a
Gly-Ser amino acid linker (GS)) was inserted between gene sequences
encoding each domain. Key leucine residues and helix-turn-helix mo-
tifs (H-T-H) are indicated. Sig., signature.
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this promoter in both the absence (264% of uninduced wild-
type UreR level) and presence (42% of urea-induced wild-type
UreR level) of urea (Fig. 2). The level of activation of pureD,
mediated by C/EBP302–350-UreR164–293 and measured by the
b-galactosidase assay, was not significantly different in the
presence and absence of urea. This result is consistent with the
urea-binding domain not residing in the C-terminal half of
UreR or urea binding not affecting DNA binding in the chi-
mera.
A UreR-Myc-His fusion was constructed so that UreR could
be readily detected on Western blots and in gel mobility shift
assays. The UreR-Myc-His fusion induced b-galactosidase ex-
pression using the pureD-lacZ reporter construct and elicited
levels of expression that were not significantly different from
wild-type UreR level (104 and 73% of wild-type UreR activa-
tion in the absence and presence of urea, respectively) (Fig. 2).
Since we observed similar b-galactosidase expression from
pureD-lacZ for both UreR and UreR-Myc-His, we considered
these two proteins to be interchangeable in their ability to
regulate transcription. This translational fusion contains a c-
Myc epitope and His6 tail that are recognized by anti-Myc
(Invitrogen) and anti-His5 (Qiagen) monoclonal antibodies,
respectively. Expression of the UreR-Myc-His protein product
was verified by Western blotting. The translational fusion pro-
tein was detected as a band corresponding to the expected
molecular size of ;36 kDa with both anti-Myc (Fig. 3F) and
anti-His (Fig. 3A) antibodies.
Neither the putative UreR DNA-binding domain alone
(amino acids 164 to 293) nor C/EBP302–350 alone activated
transcription from pureD in the presence or absence of urea;
values were below levels detected for the vector plasmid DNA
alone (Fig. 2). The stability of UreR164–293 and C/EBP302–350
was examined by translationally fusing Myc-His to the C-ter-
minal end of both truncated proteins. Both the UreR164–293
and the C/EBP302–350 proteins showed negligible b-galactosi-
dase activities that were not significantly different from their
Myc-His fusion counterparts. Western blot analysis using mono-
clonal anti-His5 (Qiagen) revealed that both the UreR164–293-
Myc-His (18 kDa) and the C/EBP302–350-Myc-His (9 kDa) are
produced (Fig. 3B and C).
DNA binding by UreR constructs assessed by gel shift. Gel
shift experiments were performed to verify that C/EBP302–350-
UreR164–293 used in the b-galactosidase assays could bind to
FIG. 2. b-Galactosidase assays using pureD-lacZ reporter construct.
b-Galactosidase activity was measured in E. coli Top10 transformed
with the pureD-lacZ reporter construct and the chimeric fusion con-
structs. Cultures (4 ml) were grown in LB medium to mid-exponential
phase and induced with 0.02% arabinose with or without 100 mM urea
for 1 h. b-Galactosidase activity is expressed in Miller units (18). All
constructs were assayed in duplicate in at least three different experi-
ments.
FIG. 3. Western blot analysis of fusion constructs. E. coli Top10 (A,
B, C, and F) or E. coli JL1436 (D and E), transformed with vector or
clones expressing UreR or chimeric proteins, was cultured in LB me-
dium to mid-exponential phase and induced with 2% arabinose for 4 h
(unless otherwise noted). Samples (10 ml) of each suspension were
boiled for 5 min in gel sample buffer and electrophoresed on an SDS-
polyacrylamide gel. Membranes were incubated with antiserum or
monoclonal antibodies and developed with secondary antibodies con-
jugated to alkaline phosphotase (Sigma). (A) pBAD, UreR, UreR-
Myc-His; 12.5% SDS-polyacrylamide gel. Membranes were reacted
with mouse anti-His antibody (diluted 1:1,000) (Invitrogen). (B)
pBAD, UreR, UreR164–293, or UreR164–293-Myc-His; 15% SDS-poly-
acrylamide gel. Membranes were reacted with mouse anti-His anti-
body (diluted 1:1,000) (Invitrogen). (C) pBAD, UreR, C/EBP302–350,
C/EBP302–350-Myc-His; 15% SDS-polyacrylamide gel. Membranes
were reacted with mouse anti-His antibody (diluted 1:1,000) (Invitro-
gen). (D) LexA, LexA1–87, LexA1–87-Myc-His; induced with 2 mM IPTG.
Samples (2 ml) of each were electrophoresed on a 15% SDS-polyacryl-
amide gel. Membranes were hybridized with rabbit polyclonal anti-
LexA antibody (diluted 1:5,000) (Invitrogen). (E) LexA, LexA1–87,
UreR1–182-LexA1–87; induced with 2 mM IPTG. Samples (1.25 ml) of
each, including strain only, were electrophoresed on a 12.5% SDS-
polyacrylamide gel. Membranes were reacted with rabbit polyclonal
anti-LexA antibody (diluted 1:5,000) (Invitrogen). (F) pBAD, UreR,
UreR-Myc-His, UreR L147A-L148A, UreR L147A-L148A-Myc-His,
UreR L147A-L148A-L158A, and UreR L147A-L148A-L158A-Myc-
His; induced with 2% arabinose for 4 h. Samples (10 ml) of each were
electrophoresed on a 12.5% SDS-polyacrylamide gel. Membranes
were hybridized with mouse anti-Myc antibody (diluted 1:5,000) (In-
vitrogen).
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pureD. A 60-bp double-stranded oligonucleotide that contained
the DNA sequence for pureD (266 to 26 upstream of the
transcriptional start of ureD) was synthesized and labeled with
DIG-11-ddUTP by terminal transferase.
Binding assays were performed with the labeled double-
stranded oligonucleotide, whole-cell extracts containing each
of the overexpressed protein products, and 100 mM urea. A
cell extract containing full-length UreR retarded the migration
of the double-stranded DNA (dsDNA) fragment, indicating
that UreR protein bound to DNA (Fig. 4). The fusion protein,
C/EBP302–350-UreR164–293, also bound the labeled DNA, re-
flected by a somewhat less intense shifted band. The UreR-
Myc-His fusion protein bound and retarded the labeled DNA
as well as full-length UreR (data not shown). The pBAD vec-
tor control lane showed a faint band at the highest concentra-
tion of lysate; however, there are no other bands evident in the
pBAD lanes containing lower concentrations of protein. The
limited nonspecific binding seen in the vector control lane can
likely be explained by the use of whole-cell extracts incubated
with the target DNA (14). These results demonstrate that
full-length UreR, C/EBP302–350-UreR164–293, and UreR-Myc-
His bind to the pureD DNA double-stranded oligonucleotide
and are likely responsible for the activation from pureD.
Localization of the UreR dimerization domain. Protein chi-
meras were constructed to localize the UreR dimerization do-
main. The gene sequence encoding the N-terminal half (amino
acids 1 to 182) of UreR was fused to the gene sequence en-
coding the LexA DNA-binding domain (amino acids 1 to 87),
forming the UreR1–182-LexA1–87 fusion protein (Fig. 1; prim-
ers are listed in Table 2). All fusion constructs used in these
experiments were cloned into pSE380 (Invitrogen) (Table 1)
under the control of an IPTG-inducible promoter. The re-
porter strain, JL1436 (Table 1), originally described by Bustos
and Schleif (2), consisted of a chromosomal transcriptional
fusion of psulA with lacZ placed downstream; the sulA gene is
repressed by dimerized LexA (2).
The fusion proteins were assayed for the ability to repress
transcription of lacZ by binding to psulA. As expected, both
untransformed E. coli JL1436 and JL1436 transformed with
full-length ureR showed no repression of b-galactosidase ex-
pression (Fig. 5). The UreR1–182-LexA1–87 fusion repressed
transcription from psulA by factors of 70 and 56 in the absence
and presence of urea, respectively, comparable to the results
for full-length LexA (the repression factor is defined as the
Miller units of the strain only divided by the Miller units of the
strain carrying the expression vector). LexA has repression
factors of 92 and 127 in the absence and presence of urea,
respectively. The LexA DNA-binding domain alone (LexA1–87)
did not repress, indicated by repression factors of only 8 in the
absence of urea and 4 in the presence of urea. As expected, the
repression factors seen for both UreR1–182-LexA1–87 and full-
length LexA are not significantly different in the absence of
urea, showing that they are similar in the ability to repress
transcription from psulA. However, both LexA and
UreR1–182-LexA1–87 had repression factors that were signifi-
cantly different (P # 0.001) from those of the LexA1–87 control
in the presence and absence of urea, suggesting that the
LexA1–87 lacks a dimerization domain that was provided by
UreR1–182 to repress transcription. UreR1–182-LexA1–87 did
not repress transcription in a urea-inducible manner.
We noted that LexA1–87 was not stable on Western blots.
Thus, to examine whether lack of repression at the sulA re-
porter was due to the lack of stability, we constructed another
control. LexA1–87 protein was translationally fused to Myc-His
at its C-terminal end. LexA1–87-Myc-His protein also did not
repress transcription from psulA, as evidenced by b-galactosi-
dase assays. LexA1–87, either tagged or not with the Myc-His
FIG. 4. Gel mobility shift assay for interaction of UreR with the
P. mirabilis pureD. A 60-bp double-stranded oligonucleotide was syn-
thesized based on the sequence of pureD. Whole-cell extracts of E. coli
Top10 transformed with either pBAD or vector expressing C/EBP302–350-
UreR164–293 were obtained by inducing a 4-ml culture in mid-exponen-
tial phase with 2% arabinose for 4 h. Whole-cell extracts of E. coli
Top10 expressing UreR and UreR-Myc-His were obtained by inducing
a 4-ml culture in mid-exponential phase with 2% arabinose and 100
mM urea for 4 h. Bacterial suspensions were adjusted to the same OD,
and 3 ml of each culture was harvested by centrifugation (10,000 3 g,
5 min, 4°C). Bacteria were resuspended in 1 ml of TEN buffer and
lysed in a French press (18,000 1b/in2). Binding reactions with the 60-
bp pureD dsDNA fragment were carried out in the presence of 100 mM
urea with various amounts of the extracts.
FIG. 5. b-Galactosidase reporter activity of the psulA-lacZ chromo-
somal fusion reporter construct in strain JL1436. E. coli JL1436 (car-
ries a single copy of a psulA-lacZ chromosomal fusion) transformed
with the chimeric fusion constructs was cultured in LB medium (4 ml)
to mid-exponential phase and induced with 2 mM IPTG with or with-
out 100 mM urea for 1 h. b-Galactosidase levels measured in Miller
units (18) as an index of expression from psulA-lacZ. The Repression
factor was calculated by dividing the Miller units for strain only
(JL1436) by Miller units for each construct in JL1436. All constructs
were assayed in duplicate for at least three independent experiments.
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epitope, showed negligible repression and values were not sig-
nificantly different.
Expression of both full-length LexA and the UreR1–182-
LexA1–87 used in the b-galactosidase assay was also verified by
Western blotting using an anti-LexA polyclonal antibody (In-
vitrogen) (Fig. 3E). Strong signals were observed in lanes con-
taining LexA and UreR1–182-LexA1–87. Western blot analysis
using anti-LexA showed a 13-kDa band corresponding to
LexA1-87-Myc-His (Fig. 3D). Therefore, the repression of b-
galactosidase expression observed in the UreR1–182-LexA1–87
b-galactosidase assay was likely due to the expression of the
fusion protein.
Binding of the UreR-LexA fusions to target DNA assayed by
gel shift. Gel shift experiments were performed to show that
the fusion proteins as well as the LexA control bound to psulA,
providing an explanation for the inhibition of transcription
initiation from psulA-lacZ. A 64-bp double-stranded oligonu-
cleotide comprising the LexA binding site upstream of sulA
(126 to 238 relative to the transcriptional start of sulA) was
synthesized and labeled with DIG-11-ddUTP by terminal trans-
ferase.
Lanes containing LexA revealed a strong signal representing
a shifted band (Fig. 6). The UreR1–182-LexA1–87 lanes con-
tained a retarded band that was not as strong in intensity. Cell
extracts from JL1436 carrying no plasmid (Fig. 6) or JL1436
transformed with the LexA1–87-Myc-His construct alone (data
not shown) were unable to retard the mobility of the dsDNA
fragment.
PCR site-directed mutagenesis of leucines in the putative
UreR dimerization domain. AraC uses three critical leucines
(Leu150, Leu151, and Leu161) for dimerization via an antipa-
rallel coiled-coil in the absence and presence of arabinose (15).
Due to the conservation of these three leucines in both overall
location and spatial orientation within UreR, we hypothesized
that these leucine residues are important for dimerization of
UreR. To directly test biologically whether these Leu residues
are required for dimerization of UreR monomers, PCR site-
directed mutagenesis (9) was used to create leucine to alanine
mutants of UreR in Leu147 (L147A) alone, Leu148 (L148A)
alone, Leu158 (L158A) alone, Leu147 and Leu148 (L147A-
L148A), and Leu147, Leu148, and Leu158 (L147A-L148A-
L158A). b-Galactosidase expression from the pureD-lacZ re-
porter plasmid was measured for each of the UreR leucine
mutants in the presence and absence of urea (Fig. 7). In the
presence of urea, the L147A, L148A, and L158A single mu-
tants had levels of expression that were 71, 89, and 137%,
respectively, of the wild-type UreR level. Thus, dimerization,
required for activity, was not dramatically altered. The L147A-
L148A double mutant, however, had an expression level that
was only 15% of the wild-type UreR level in the presence of
urea, a significant drop in activity (P , 0.001). The expression
level observed for the L147A-L148A-L158A triple mutant,
6% of the wild-type UreR level (P , 0.001) in the presence of
urea, tended to be even lower than that of the double mutant
(P 5 0.052).
To verify that both the double and triple mutant proteins
were expressed and stable, L147A-L148A and L147A-L148A-
L158A were translationally fused to Myc-His. The L147A-
L148-Myc-His protein activated from pureD to the same degree
(15 and 8% of the wild-type UreR level in the absence and
presence of urea, respectively) as seen for L147A-L148A pro-
tein in the b-galactosidase assay. The L147A-L148A-L158A-
Myc-His protein activated from pureD to the same degree (11
and 4% of the wild-type UreR level in the absence and pres-
ence of urea, respectively) as seen for L147A-L148A-L158A
protein in the b-galactosidase assays. Western blot analysis
using monoclonal anti-Myc antibodies (Invitrogen) confirmed
the stable expression of two 36-kDa bands corresponding to
L147A-L148A-Myc-His and L147A-L148A-L158A-Myc-His
(Fig. 3F).
Dimer formation in UreR derivatives. To determine wheth-
er the low activity of the triple Leu mutant of UreR-Myc-His
was due a loss of dimerization, we compared the elution profile
FIG. 6. Gel mobility shift assay for chimeric protein and the LexA
DNA-binding site upstream of psulA. A 64-bp double-stranded oligo-
nucleotide was synthesized based on the nucleotide sequence of psulA.
Whole-cell extracts were obtained by inducing a 100-ml culture, in
mid-exponential phase, with 2 mM IPTG for 3 h. Culture (50 ml) was
centrifuged, and bacteria were resuspended in 1 ml of TEN buffer and
lysed in a French press (18,000 lb/in2). All lanes contained the labeled
64-bp dsDNA fragment. The lane containing no extract contained
labeled DNA only. JL1436, LexA, and UreR1–182-LexA1–87 whole-cell
extracts were added at volumes of 10, 5, and 1 ml.
FIG. 7. b-Galactosidase assays using the pureD-lacZ reporter con-
struct to measure activation by the UreR leucine mutants. E. coli trans-
formed with the Leu mutant constructs was cultured to mid-log phase
in LB medium (4 ml) and induced with 0.02% arabinose with or with-
out 100 mM urea for 1 h. b-Galactosidase activity represented expres-
sion from pureD-lacZ and is expressed in Miller units. All constructs
were assayed in duplicate for at least three independent experiments.
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of this protein to that of UreR-Myc-His on a Sephadex G-75
gel filtration column. The two proteins, purified from induced
cell lysates on a Ni-nitrilotriacetic acid column, were applied to
the column. Both UreR-Myc-His and the L147A-L148A-L158A-
Myc-His derivative of UreR eluted at fractions corresponding
to the dimerized protein (Fig. 8). Thus, loss of activity in the
site-directed mutant was not due to the inability to dimerize.
Constitutive induction of urease genes by His mutants of
UreR. We did not observe urea inducibility using the chimeric
fusion proteins. We had reasoned earlier, however, that histi-
dine residues were likely involved in either urea binding or
transmission of a structural alteration induced by urea activa-
tion to the DNA-binding domain. Indeed, the active site of
urease coordinates urea by interaction with four His, one Cys,
one Asp, and one Lys residue (18). Thus, urea could be coor-
dinated by similarly configured His residues within UreR. Us-
ing site-directed mutagenesis, eight His residues were changed
to Ala. Six mutations (H5A, H73A, H107A, H186A, H129A,
and H152A) did not significantly alter urea inducibility of
the mutated UreR (data not shown). Two of eight His-to-Ala
mutants tested, however, H102A and H175A, constitutively
induced urease genes (i.e., in the absence of urea), as assayed
using the ureD-lacZ translational fusion to levels that were not
significantly different from the wild-type UreR level in the
presence of urea (Table 3). The His102 residue resides in the
N-terminal domain, the region predicted to bind urea. Inter-
estingly, the His175 residue resides in the linker region that
joins the dimerization domain and DNA-binding domain.
DISCUSSION
UreR chimeric proteins were constructed to identify and
localize functional domains of the AraC-like transcriptional
activator of the P. mirabilis urease gene cluster. Our studies led
us to conclude that the N-terminal half of UreR contains the
dimerization domain and the C-terminal half of UreR serves as
the DNA-binding domain. Leucine residues in the putative
dimerization domain of UreR, conserved with respect to AraC
and other UreR homologues, were required to fully activate
transcription. Site-directed mutagenesis studies were consis-
tent with their involvement in dimerization. While it is pro-
posed that urea binding by UreR is required for activation,
construction of the chimeric proteins did not allow us to elu-
cidate this role. Two His mutants of UreR, however, displayed
constitutive induction of urease genes.
Our experimental results support the hypothesis that the
dimerization domain of UreR localizes to the N-terminal half
of UreR. Repression of psulA-lacZ by UreR1–182-LexA1–87 is
consistent with the presence of a dimerization domain supplied
by UreR. LexA1–87 alone was unable to repress transcription
from psulA-lacZ (Fig. 5). Only when the N terminus of UreR
was fused to LexA1–87 was repression evident, indicating the
requirement for dimerization. Other studies have demonstrat-
ed that the LexA1–87 as well as the l repressor requires a
dimerization domain for full function (8, 10, 22). That dimer-
ization occurs in the fusion protein is further supported by the
observation that UreR1–182-LexA1–87 is capable of retarding
the mobility of a double-stranded oligonucleotide containing
the sulA promoter in a gel shift assay (Fig. 6). LexA1–87-Myc-
His, a stably expressed protein, does not retard the mobility of
the target DNA. Thus, the addition of a dimerization domain,
provided by the UreR N-terminal amino acid sequences, to
LexA1–87 is necessary and sufficient to restore the DNA-bind-
ing capability of LexA1–87 for its target, psulA.
A number of observations also led us to conclude that
the DNA-binding domain resides in the C-terminal half of
UreR. We demonstrated that a functional chimeric protein,
C/EBP302-350-UreR164–293, binds to a double-stranded oligonu-
cleotide containing the mapped UreR-binding site (25) within
pureD (Fig. 4). The UreR-binding site, mapped by Thomas and
Collins, is 257 to 234 upstream of the transcriptional start of
ureD in the P. mirabilis ureR-ureD intergenic region (25). Inte-
restingly, C/EBP302–350-UreR164–293 activated transcription from
pureD to the same degree in both the absence and presence of
urea (Fig. 2). This finding is consistent with the hypothesis that
the putative urea-binding site resides in the nonhomologous
N-terminal domain. The C/EBP302–350-UreR164–293 fusion has
slightly less than optimal activation in comparison to UreR.
This may have resulted from constraints imparted on the
UreR164–293 by the heterologous C/EBP dimerization domain.
FIG. 8. Gel filtration chromatography of UreR-Myc-His and its
triple Leu mutant. Purified UreR-Myc-His and UreR-L147A-L148A-
L158A-Myc-His (3 X Leu mutant) (approximately 10 mg of protein)
were applied to a Sephadex G-75 column. Protein elution was moni-
tored at 280 nm. Fractions (0.5 ml) were collected, and aliquots of the
3 X Leu mutant (0.15 ml) were assayed by immunoblotting using
anti-Myc antibodies (positioned above peak fractions). The elution
volumes of bovine serum albumin (BSA) and carbonic anhydrase (CA)
are indicated by arrows. The inset shows Western blot of lysates used
for purification, run on a denaturing gel, and developed using anti-Myc
antibodies. The apparent molecular size is noted.
TABLE 3. Induction of Urease Genes by His mutants of UreR
E. coli Top10 (pureD-lacZ)
cotransformed with:
b-Galactosidase activity
(Miller units 6 SD)
0 mM urea 100 mM urea
pBAD (vector control) 53 6 15 51 6 17
pCP016 (UreR) 627 6 204 3,654 6 1442
pCP063 (UreRHis102Ala) 2,414 6 522
a,b 4,229 6 296c
pCP056 (UreRHis175Ala) 2,871 6 43
a,c 4,770 6 262c
a P , 0.001 compared to uninduced (0 mM urea) UreR.
b P 5 0.16, not significantly different from induced (100 mM urea) UreR.
c P . 0.2, not significantly different from induced (100 mM urea) UreR.
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The ability of the C/EBP302–350-UreR164–293 to bind and acti-
vate transcription from pureD is consistent with DNA-binding
specificity residing in the putative UreR DNA-binding domain.
This assertion is further supported by the observation that in
the absence of a dimerizing mechanism, the UreR DNA-bind-
ing domain alone was unable to activate transcription from
pureD-lacZ even though UreR164–293 could recognize its target
sequence (Fig. 2) when dimerized. Furthermore, these results
suggest that a dimerization domain, provided by C/EBP in this
case, is necessary and sufficient to allow the binding of the
C-terminal portion of UreR to the ureD promoter. Taken to-
gether, these results suggest that, as in other AraC family mem-
bers, dimerization of UreR is required for activation of urease
promoters and that the DNA-binding domain, rather than the
dimerization domain, resides in the C-terminal portion of
UreR.
UreR activates transcription from both pureD and pureR in
a urea-inducible manner (6), leading to the hypothesis that
UreR binds urea. Likely, this mechanism involves a structural
change induced by urea binding. We also hypothesized that
because the AraC family of transcriptional regulators contains
little or no homology in the N-terminal portion of the proteins,
binding specificity for an inducer molecule would likely reside
in the N-terminal portion of the protein (7). Although UreR1–182-
LexA1–87 represses transcription from psulA-lacZ, the hypoth-
esized urea requirement for UreR function was not observed
in the b-galactosidase assays (Fig. 5). The tertiary structure of
the UreR1–182-LexA1–87 fusion appears to allow for UreR
dimerization to occur but clearly eliminates the urea-inducible
mechanism. If UreR dimerizes via two different conformations
depending on whether urea is present or not, then possibly
only one of the dimerization conformations is attainable when
fused to LexA1–87, allowing for binding of the UreR1–182-
LexA1–87 fusion to psulA-lacZ. This may account for the unre-
sponsiveness of UreR1–182-LexA1–87 to urea.
Nevertheless, some clues as to the mechanism of urea in-
ducibility by UreR were uncovered by site-directed mutagen-
esis. Interestingly, among eight His-to-Ala mutants of UreR
tested for urea inducibility, two resulted in constitutive tran-
scriptional activation from the ureD promoter in the absence of
urea. His102 resides in the putative urea-binding (N-terminal)
domain. His175 resides in the amino acid sequence that com-
prises a linker region between the N-terminal and C-terminal
domains. It could be speculated that this latter residue trans-
mits the structural alteration that follows urea binding to the
C-terminal DNA-binding domain, resulting in binding to spe-
cific DNA sequences within the ureR-ureD intergenic region.
AraC dimerizes via an antiparallel coiled-coil containing
three leucines that fits into a knobs-into-holes conformation at
both ends of the coil (23, 15). UreR retains these three con-
served leucines in the same spatial orientation and relative
location. PCR site-directed mutagenesis of Leu147, Leu148,
and Leu158 in UreR demonstrates the requirement of these
residues for transcriptional activation of pureD-lacZ (Fig. 7).
The levels of transcriptional activation for each of the single
leucine mutants of UreR are not significantly different from
the wild-type UreR level in the presence of urea. The double
and triple leucine mutants, however, show a dramatic decrease
in activation in comparison to both wild-type UreR and the
single leucine mutants in both the presence and absence of
urea (as little as 6% of native UreR activity). These results
indicate that alteration of each one of the leucines alone is not
sufficient to disrupt the protein structure to any degree in the
presence of urea. However, because both Leu147 and Leu148
from one monomer may flank Leu158 from the other mono-
mer and act as a dimerization anchor at each end of the coiled-
coil helix, the mutation of both Leu147 and Leu148 would be
expected to perturb the native dimerization state. A mutation
in one of the leucines still may allow for the interaction be-
tween the nonmutated leucine and Leu158 from the other
monomer. However, mutation of both Leu147 and Leu148
may eliminate the pocket into which Leu158, from the other
monomer, is anchored. Surprisingly, while the native dimeriza-
tion state may have been altered, the triple Leu mutant re-
mained a dimer. The purified Myc-His derivative of the triple
mutant eluted at the identical fraction as purified UreR-Myc-
His on a gel filtration column (Fig. 8), indicating that under
physiologic conditions the two monomers remained associated.
More drastic amino acid substitutions of the homologous res-
idues (Leu to Lys in combination with Leu to Ser) in a con-
struct expressing the N-terminal half of AraC did disrupt the
dimeric state to yield the monomers (15). Likely, this would be
the case for UreR as well. In this study, the Leu residues were
conservatively changed to only Ala. While this study is the first
to show the biological relevance of these critical leucine resi-
dues in UreR, clearly additional studies are required to sub-
stantiate their precise role.
The UreR-Myc-His fusion was constructed to detect and
follow a protein that mimics wild-type UreR in vivo and in
vitro. Although UreR-Myc-His contains the c-Myc and His6
epitopes at the C terminus of UreR, b-galactosidase reporter
activity demonstrated that UreR-Myc-His activated transcrip-
tion from pureD-lacZ as well as wild-type UreR (Fig. 2). Over-
expression of UreR-Myc-His and detection by anti-Myc and
anti-His antibodies on a Western blot show that the fusion
protein was produced (Fig. 3). Furthermore, gel mobility shift
assays demonstrated that UreR-Myc-His was able to bind to
pureD, which resulted in a strong shift of labeled target DNA
comparable to the shift seen with wild-type UreR (data not
shown).
Using protein fusion technology, we have provided evidence
that the AraC-like transcriptional activator UreR consists of
dimerization and DNA-binding domains. We have also eluci-
dated a possible dimerization mechanism based on the knobs-
into-holes conformation facilitated by three leucine residues
that are conserved within both UreR and AraC. Our chimeric
proteins were unresponsive to urea activation, and thus a urea-
binding domain could not be assigned although we identified
two key His residues that were involved in urea inducibility.
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